

***EUROGUIDERM GUIDELINE ON **ATOPIC
ECZEMA**—
METHODS REPORT***

Version 4.0, Dec. 2025

Kinberger M, Heuer R, Dressler C, Nast A, Avila Valle G, Werner RN

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Table of Contents

Notes on use/Disclaimer	3
Funding (standard) Statement	3
Involving stakeholders and establishing the guideline subcommittee	3
Declaration and management of conflicts of interest	6
Scoping and defining the purpose of the guideline	7
Search methods and results, evidence selection & critical appraisal of evidence	13
Developing background texts	14
Developing recommendations and the consensus process	15
Online pre-voting	16
Consensus conferences	17
Internal and external review	18
Dissemination and Implementation	19
Quality standards and monitoring indicators	19
Evaluation Methods	19
Patient-perspective and needs	19
Strength and Limitations	20
Update and Methods	20
References	31
Appendices	36

Notes on use/Disclaimer

This is the methods report of the evidence and consensus based EuroGuiDerm Atopic Eczema Guideline.

This work is licensed under the Creative Commons Attribution-NonCommercial 4.0.

Funding (standard) Statement

The development of this EuroGuiDerm guideline was funded through the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision making on which guideline (GL) or consensus statement (CS) development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting the EuroGuiDerm is never involved in the guideline development and had no say on the content or focus of the guideline.

Involving stakeholders and establishing the guideline subcommittee

In December and January 2019/2020, invitations were sent out to all EuroGuiDerm funding societies (n=12). Each society was asked to nominate a candidate to partake in the guideline development process, see Table 1. We also made public announcements to all European Dermatology Forum (EDF) members and used social media to call for participation.

The link to the EuroGuiDerm standardized online declaration of interests form was sent via electronic mail to all chosen experts and each of them had to declare: 1) personal-financial interests (PF), 2) non-personal financial interests (NP-F), and 3) their personal non-financial interests (P-NF). The EuroGuiDerm Board of Directors made the final decision on which candidates may participate considering their self-reported PF interests. Experts were informed afterwards about the decision through e-mail.

TABLE 1: MEMBERS OF THE GUIDELINE DEVELOPMENT GROUP

Title	Last name	First name	Institution	Expertise	Country	Role
	Arents	Bernd	European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels	patient	Netherlands	Co-author, patient representative
Dr.	Aszodi	Nora	Department of Dermatology, LMU Munich	clinical	Germany	Co-author
Prof. Dr.	Barbarot	Sebastien	University hospital, Nantes	primary prevention, education	France	Co-author
Prof. Dr.	Bieber	Thomas	Department of Dermatology and Allergy, University Hospital of Bonn	drug trials	Germany	Co-author
Dr.	Brough	Helen A.	Department of Pediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's College London and Guy's and St. Thomas' NHS	paediatric allergy and clinical immunology	United Kingdom	Co-author

			Foundation Trust, London, United Kingdom			
Prof. Dr.	Calzavara Pinton	Piergiacomo	Dermatology Department, University of Brescia	phototherapy	Italy	Co-author
Dr.	Christen-Zäch	Stéphanie	University Hospital Lausanne	pediatric dermatology	Switzerland	Co-author
Dr.	Deleuran	Mette	Aarhus University Hospital	systemic treatments, immunodermatology	Denmark	Co-author
Dr. oec. troph.	Fink-Wagner	Antje-Henriette	Global Allergy and Airways diseases Patient Platform GAAPP, Vienna	patient representative	Germany	Co-author, patient representative
Prof. Dr.	Flohr	Carsten	St John's Institute of Dermatology, King's College London	methodologist, clinical, systemic therapy	United Kingdom	Coordinator, co-author and methodologist (NMA)
Dr.	Fosse	Nicole	Department of Dermatology, University Hospital Basel	dermatology	Switzerland	Co-author
Dr.	Gáspár	Krisztián	Dept. of Dermatology and Dept. of Dermatological Allergology of the University of Debrecen	dermato-immunologist	Hungary	Co-author
Dr.	Gerbens	Louise	Amsterdam UMC (University Medical Centers), department of Dermatology	resident dermatology, PhD in atopic eczema, systemic therapy methodologist	Netherlands	Co-author
Prof. Dr.	Gieler	Uwe	Dept. Dermatology, Univ. Giessen	psychodermatology	Germany	Co-author
Prof. Dr.	Girolomoni	Giampiero	Dermatology and Venereology Section, Department of Medicine, University of Verona	immunobiology, treatments	Italy	Co-author
Prof. Dr.	Gregoriou	Stamatis	National and Kapodistrian University of Athens, Faculty of Medicine, Athens	Clinical	Greece	Co-author
Prof. Dr.	Moertz	Charlotte	Dept. of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark	clinical, dermatology, allergology	Denmark	Co-author
MD PhD	Nygaard	Uffe	Dept. of Dermato-Venerology, Aarhus University Hospital	immunobiology, Skin barrier, Biomarkers	Denmark	Co-author

	Redding	Magali	Eczema Outreach Support (UK)	Founding CEO of Eczema Outreach Support (UK), mother of a child with eczema	United Kingdom	Co-author, patient representative
MD, PhD	Rehbinder	Eva Maria	Dermatology Department, Oslo University Hospital	atopic dermatitis	Norway	Co-author
Prof. Dr. Dr.	Ring	Johannes	Dept Dermatology Allergology Biederstein, Technical University Munich	dermatology, immunology, allergy	Germany	Co-author
Dr.	Rossi	Mariateresa	Dermatology Unit Spedali Civili Hospital Brescia	phototherapy	Italy	Co-author
Dr.	Serra-Baldrich	Esther	Dermatology, Hospital of Sant Pau	clinical	Spain	Co-author
Prof. Dr.	Simon	Dagmar	Department of Dermatology, Inselspital, Bern University Hospital, University of Bern	clinical	Switzerland	Co-author
Prof. Dr.	Szalai	Zsuzsanna Zsófia	Pediatric dermatology unit, Heim Pál National Children's Institute Budapest	pediatric dermatology	Hungary	Co-author
Prof. Dr.	Szepietowski	Jacek C.	Department of Dermatology, Venereology and Allergology, Wrocław Medical University	pruritus	Poland	Co-author
Dr.	Torrelo	Antonio	Hospital Infantil Niño Jesús, Madrid	pediatric dermatology	Spain	Co-author
Prof. Dr.	Werfel	Thomas	Hannover Medical School	Immunodermatology and allergology	Germany	Co-author
Prof. Dr.	Wollenberg	Andreas	Department of Dermatology, LMU Munich	clinical	Germany	Coordinator and co-author
EuroGuiDem Team						
	Avila Valle	Gabriela	Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin	systematic review methods	Germany	MD, Methodologist
	Dittmann	Martin	Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin	information specialist	Germany	Team support, information specialist.
Dr.	Dressler	Corinna	Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin	Systematic review methods	Germany	Methodologist, Deputy Lead EuroGuiDerm

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Dr.	Kinberger	Maria	Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin	Systematic review methods	Germany	MD, Methodologist
Prof. Dr.	Nast	Alexander	Division of Evidence Based Medicine (dEBM), Charité - Universitätsmedizin Berlin	Systematic review methods; certified guideline facilitator	Germany	MD, Methodologist: Director EuroGuiDerm

Declaration and management of conflicts of interest

We requested that experts declare their interests personally as described above through the online tool: **Declaration of Interests for EuroGuiDerm Guidelines** (<http://ask.debm.de/index.php/981542?lang=en>).

In line with the EuroGuiDerm Methods Manual, all experts can take part in the discussion. However, declaring personal-financial interests means that the person is not eligible to vote on recommendations. Of the 29 members of the guideline development group (GDG), 41.3 % (n=12) reported having personal-financial interests, see Table 2. 58.6% (n=17) of members reported having no personal-financial interests. Experts who had declared to have personal-financial COIs were not allowed to vote on the recommendations for systemic treatment including those pertaining to pregnancy.

TABLE 2: DECLARATIONS OF PERSONAL-FINANCIAL CONFLICTS OF INTERESTS AS PROVIDED BY EXPERT

Title	First name	Last name	As declared by the person:
Prof. Dr.	Sebastien	Barbarot	Dr Barbarot personal fees from Bioderma, Laboratoire La Roche Posay, Sanofi-Genzyme, AbbVie, Novartis, Janssen, Leo-Pharma, Pfizer, Lilly, UCB, Fresenius-Kabi, Samsung bioepis, Biogen
Prof. Dr.	Thomas	Bieber	T. Bieber is/has been lecturer and/or consultant for following companies: AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, Böhringer-Ingelheim, Daichi-Sankyo, Davos Biosciences, Dermavant/Roivant, DS Pharma, Evaxion, FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GSK, Incytes, Kymab, LEO, Lilly, L'Oréal, MenloTx, Novartis, Pfizer, Pierre Fabre, Sanofi/Regeneron, UCB
Dr.	Mette	Deleuran	Participation in advisory boards and/or speaker for Sanofi-Genzyme, Regeneron, Galapagos, Eli-Lilly, Pfizer, Leo-Pharma, Pierre Fabre Dermo-cosmetique, Almirall, and AbbVie
Prof. Dr.	Giampier	Girolomoni	Personal fee for attending advisory boards or as a speaker at sponsored meetings from Sanofi, Regeneron, Galderma, Almirall, Abbvie, Pfizer, Leo pharma, Novartis, Eli Lilly
MD PhD	Uffe	Nygaard	Received honorary from Sanofi Genzyme A/S for teaching and providing written patient information regarding AE.
Prof. Dr. Dr.	Johannes	Ring	Honoraria for lectures Abbvie, Allergika
MD PhD	Rehbinder	Eva Maria	Received honoraries for lectures from Sanofi Genzyme, Leo Pharma, Novartis, Norwegian Psoriasis and Eczema Association, Norwegian Asthma and Allergy Association ¹

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Dr.	Serra-Baldrich	Esther	Honorary as speaker, consultant , boards, for Pfizer, Sanofi, Novartis, Lilly, Abbvie, Galderma, Leo
Prof. Dr.	Jacek C.	Szepietowski	Advisory Board Member of Leo Pharma Speaker for Leo Pharma and Sanofi-Genzyme Investigator for Regeneron, Pfizer
Dr.	Antonio	Torrelo	Lilly, Sanofi, Pierre Fabre, Pfizer, Abbvie - All advisory boards and/or lectures and/or clinical trials
Prof. Dr.	Thomas	Werfel	Advisor and Research Funding from companies currently active in AE Research: Sanofi, Lilly, Pfizer, LEO, Galderma
Prof. Dr	Andreas	Wollenberg	AbbVie, Lilly, Pierre Fabre, Sanofi, Galderma, L'Oreal, Leo, Novartis
¹ declared in September 2021			

Scoping and defining the purpose of the guideline

The EuroGuiDerm team (CD and GA) and the guideline coordinators (AW and CF) prepared a scoping document. The manuscript was sent to the EDF members and the EuroGuiDerm Board of Directors in April 2020 for commenting and approval, see Appendix 2.

This guideline is an update of the consensus-based European guideline for the treatment of atopic dermatitis published in 2018. The guideline coordinators (AW and CF) developed 14 key questions, taking into account topics encompassed in the previous guideline but also covering new areas, in particular novel systemic medications and the management of atopic eczema in special populations (e.g. children, adolescents and pregnancy), also taking into account specific circumstances (e.g. pruritus, concomitant allergic diseases and occupational aspects). All key questions were presented to the GDG during the first online conference on 27 April 2020 and all GDG members could modify key question(s) for their assigned topic(s)/chapter(s) if required. New key questions were developed for the following sections: avoidance strategies, paediatrics and occupational aspects, see Table 3.

TABLE 3: OVERVIEW OF KEY QUESTIONS, SYSTEMATIC REVIEWS & METHODS

	Topic	Key Question(s) (KQ)	Methods	Identified systematic reviews
Consensus-based recommendations	Patient's perspective	What is the patient's or caregiver's perspective on living with AE? What are therefore the needs in terms of treatment and delivering care?	Narrative review	-
	General measures and avoidance strategies	Can the presence of pollen, animal dander, physical activity, perspiration, irritating clothing, psychological stress, pollution, tobacco provoke and elicit the development of skin symptoms in atopic patients? Can the avoidance of these above mentioned factors help to prevent the exacerbation of AE? Does the avoidance of AE triggers allow for longer remission periods or complete clearance of AE? Can individual prevention measures be identified in patient with AE?	Center of Evidence Based Dermatology (CEBD) screened for Cochrane review on house dust mite, pollen and animal dander on 19 March 2020; expanded on 01 July 2020 to include pollutants, tobacco smoke, sweat, clothing and stress; update of the search in MEDLINE (Ovid) for each of the identified systematic reviews.	"House dust mite reduction and avoidance measures for treating eczema." Nankervis et al. 2015 ¹ (Cochrane Review) "Air pollution and atopic eczema: Systematic review of findings from environmental epidemiological studies." Krämer & Behrendt. 2019 ² "A systematic review of vigorous physical activity in eczema" Kim & Silverberg 2016 ³ "Fabric selection in atopic dermatitis: An evidence-based review." Jaros et al. 2020 ⁴ "The association between maternal stress and childhood eczema: a systematic review". Chan et al. 2018 ⁵ "Prenatal maternal psychosocial stress and offspring's asthma and allergic disease: A systematic review and meta-analysis". Flanigan et al. 2018 ⁶
Consensus-based recommendations	Basic emollient treatment and bathing	What basic treatments are effective and safe and can be recommended in patients with AE?	CEBD screened up to 19 March 2020., update search run for both of the identified reviews in MEDLINE (Ovid) and Embase (Ovid).	"Emollients and moisturisers for eczema." van Zuuren et al. 2017 (Cochrane Review) ⁷ "Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis" Gonzalez-Lopez et al. 2017 ⁸

Consensus-based recommendations	Dietary intervention	Are diagnostic procedures for the elucidation of IgE-mediated food allergy (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests) routinely recommended in AE patients with a history of food-induced immediate symptoms? Are diagnostic procedures for the elucidation of combined reactions to foods (immediate reactions plus food-induced eczema (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests) recommended in AE patients with a history of food-induced symptoms including worsening of eczema? Are diagnostic procedures for the elucidation of food as a trigger factor of AE (food specific IgE and/or SPT, elimination diets and challenge tests) recommended in AE patients with a history or suspicion of food-induced eczema? Is a therapeutic elimination diet recommended after the individual diagnosis of food allergy for food-induced AE? Are general dietary interventions (e.g. supplements of vitamins, general avoidance of certain foods e.g. cow's milk, gluten) recommended for the management of AE? Are probiotics recommended for the management of AE?	CEBD screened up to 19 March 2020; update search run for the identified review in MEDLINE (Ovid) and Embase (Ovid);	"Probiotics for treating eczema." Makrgeorgou et al 2018 (Cochrane Review) ⁹ "Oral evening primrose oil and borage oil for eczema." Bamford et al. 2013 (Cochrane Review) ¹⁰ "Dietary supplements for established atopic eczema." Bath-Hextall et al. 2012 (Cochrane Review) ¹¹ "Dietary exclusions for established atopic eczema." Bath-Hextall et al. 2008 (Cochrane Review) ¹²
	Topical anti-inflammatory therapy	What is the efficacy (improvement in short and long-term disease control) and safety of topical anti-inflammatory therapies of AE?	CEBD screened on 5 May 2020.	"Systematic review and meta-analysis comparing topical corticosteroids with vehicle/moisturizer in childhood atopic dermatitis." Fishbein et al. 2019 ¹³ "Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials" Abędź & Pawliczak. 2019 ¹⁴ "Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: Systematic literature review and network meta-analysis" Fahrback et al. 2020 ¹⁵ "Topical tacrolimus for atopic dermatitis". Martins et al. 2015 (Cochrane review) ¹⁶
	Phototherapy	What is the efficacy and safety of different photo(chemo)therapy modalities (e.g. NB-UVB, PUVA, UVA1) for AE patients?	CEBD screened up to 19 March 2020,	"Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research." Garritsen et al. 2014 ¹⁷

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

	Anti-pruritic therapy	Are there specific treatment options alleviating itch in AE?	CEBD screened up to 19 March 2020.	"Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema" Matterne et al. 2019 (Cochrane Review) ¹⁸
	Antimicrobial therapy	What is the effectiveness and safety of different antibacterial, antiviral and antifungal treatments for infectious complications and alongside standard and/or systemic therapy for maintenance treatment?	CEBD screened up to 19 March 2020.	"Interventions to reduce Staphylococcus aureus in the management of eczema." George et al. 2019 (Cochrane Review) ¹⁹ "The role of yeast in atopic dermatitis revisited: a critical appraisal." Tsakok et al. 2015 ²⁰
Evidence-based recommendations	Systemic immunosuppressive treatment	What is the efficacy (improvement in short and long-term disease control (signs and symptoms) as well as quality of life) and safety of conventional and novel systemic therapies for the treatment of AE? Would changing from one systemic treatment to another lead to benefit in disease control?	CEBD screened up to 19 March 2020. A living systematic review with network meta-analysis was included and EtD Frameworks were developed.	"Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis." Drucker et al. 2020 ²¹ (living systematic review) <i>Evidence to decision frameworks were developed.</i>
	Biologics JAK inhibitors	Does combination therapy of systemic treatments lead to additional benefit in disease control and quality of life?		
Consensus-based recommendation	Other systemic treatment	What is the effectiveness and safety of other systemic anti-inflammatory agents for AE?	CEBD screened up to 19 March 2020.	"Leukotriene receptor antagonists for eczema" Ferguson et al. 2018 (Cochrane Review) ²²
Consensus-based	Allergen-specific immunotherapy	What is the effectiveness and safety of allergen-specific immunotherapy for AE patients?	CEBD screened up to 19 March 2020.	"Specific allergen immunotherapy for the treatment of atopic eczema." Tam et al. 2016 (Cochrane Review) ²³
	Complementary medicine	What is the effectiveness and safety of complementary therapies for AE patients?	CEBD screened up to 19 March 2020; results assessed with AMSTAR-2.	"Topical application of Chinese herbal medicine for atopic eczema: a systematic review with a meta-analysis." Gu et al. 2014 ²⁴ "Chinese herbal medicine for atopic eczema" Gu et al. 2013 (Cochrane Review) ²⁵ "Alpine climate treatment of atopic dermatitis: a systematic review." Fieten et al. 2015 ²⁶ "The effectiveness and safety of acupuncture for patients with

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

				atopic eczema: a systematic review and meta-analysis." Jiao et al. 2019 ²⁷ "Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials." Lu et al. 2018 ²⁸ "Effectiveness and safety of herbal medicine for atopic dermatitis: an overview of systematic reviews". Kwon et al 2020 ²⁹
Consensus-based recommendations	Psychosomatic counselling and educational interventions	What is the effectiveness of psychological and educational interventions for AE patients?	CEBD screened up to 5 May 2020, results assessed with AMSTAR-2.	"Psychological and educational interventions for atopic eczema in children." Ersner et al. 2014 (Cochrane Review) ³⁰ "Psychological and educational interventions for Atopic Dermatitis in Adults: a Systematic Review and Meta-analysis". Hashimoto et al. 2017 ³¹ "Systematic review of self management interventions for people with eczema". Ridd et al. 2017 ³² "Efficacy of health education on treatment of children with atopic dermatitis: a meta-analysis of randomized controlled trials". Li et al. 2020 ³³
Consensus-based recommendations	NEW: Considerations for pregnancy, breastfeeding or planning to have a child	What are the key differences in the management of AE in pregnant or breastfeeding women and for adults planning to have a child?	No systematic reviews were screened in the CEBD website for the KQ. Authors carried out a topic specific search in PubMed and a recent European task force position paper was considered.	"European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period." Vestergaard et al. 2019 ³⁴

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Evidence-based recommendations	NEW: Considerations for pediatric and adolescent patients	Do paediatric AE patients show important phenotypic and diagnostic differences? Are there any differences between paediatric/adolescent and adult AE patients with regard to: - the use of basic emollient therapy and other aspects of skin? - the use of topical anti-inflammatory therapy? - the use of systemic anti-inflammatory therapy? - the use of adjuvant supportive measures?	A living systematic review with network meta-analysis was included, EtD Frameworks for systemic treatments were developed	"Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis." Drucker et al. 2020 ²¹
Consensus-based recommendations	NEW: Occupational aspects	What is the impact of AE on work life? Which risks do AE patients have when starting/during work life? How to counsel AE patients regarding work life?	No systematic reviews were screened for the KQ. Authors carried out a topic specific search in PubMed and did a narrative review of the evidence available.	"The impact of atopic dermatitis on work life - a systematic review." Nørreslet et al. ³⁵

Search methods and results, evidence selection & critical appraisal of evidence

As part of the scoping exercise, we searched for existing guidelines, which did not lead to the identification of high quality (AGREE 2 evaluation) guidelines more recent than the 2018 version suitable for adaptation. We also developed the PICO framework for all key questions concerning systemic treatment, see **Appendix 2**. The living network meta-analysis (NMA), including GRADE assessments, on systemic immunomodulatory treatment for atopic eczema, which one of the guideline coordinators is leading on, was identified.²¹ Since the aim is to create a living guidelines, this systematic review is the most suitable one to use as evidence base.

Hence, the chapters on conventional systemic drugs (azathioprine, ciclosporin and methotrexate), biologics (dupilumab) and JAK-inhibitors (baricitinib) as well as systemic treatment for pediatric and adolescent populations are evidence-based.

Based on the results by Drucker et al.²¹ (2020, original publication), we developed Evidence to Decision (EtD) frameworks that enclosed the following information: population, intervention, comparison, main outcomes, setting, perspective, background, desirable and undesirable effects, certainty of evidence, balance of effects, values, resources required, cost-effectiveness, equity, acceptability and feasibility.

For the subsections on the importance of the issues, equity, acceptability and feasibility we conducted a narrative review, see Table 4.

TABLE 4: NARRATIVE REVIEW ON PATIENT/CARER NEEDS OR PREFERENCES

Key Question PICOS	What are the relevant stakeholders' views, needs or preferences concerning atopic eczema management?
Population	Adults and children (including their caretakers/families) with a clinical diagnosis of atopic dermatitis; carers; health care professionals
Context	Europe
Study design	SR, Qualitative research, surveys/questionnaire studies, discrete choice experiments, and similar
Source	Centre of Evidence Based Dermatology (CEBD) systematic lists ³⁶ ; MEDLINE
Search strategy for stakeholders preferences used in MEDLINE (Ovid) 17 March 2020	
1. ((patient\$ or subject\$ or child\$ or stakeholder or adolesc\$ or teenager) adj3 (need* or view* or prefer*)).ab,ti.	
2. ((patient\$ or child\$) adj3 (survey or questionnaire or discrete choice or interview*)).ab,ti.	
3. ((Psycho social or psycho\$ social) adj3 (need* or view* or prefer* or educat\$)).ab,ti.	
4. 1 or 2 or 3	
5. exp Dermatitis, Atopic/	
6. atopic dermatitis.ab,ti.	
7. atopic eczema.ti,ab.	
8. 5 or 6 or 7	
9. 4 and 8	
10. limit 9 to yr="2010 -Current	

Two EtD frameworks were developed on the following main questions: 1) What is the efficacy (improvement *short-term* disease control [signs and symptoms] as well as quality of life) and safety of conventional and novel systemic therapies for the treatment of AE? This includes the subgroup considerations: children and adolescents, and 2) What is the efficacy (improvement *long-term* disease control [signs and symptoms] as well as quality of life) and safety of conventional and novel systemic therapies for the treatment of AE? see evidence report.

Identification of literature concerning the remaining chapters

All other chapters are consensus-based chapters. Nevertheless, the EuroGuiDerm Team supported authors groups by searching for existing systematic reviews. To do so, we used the resources made available by the Centre of Evidence Based Dermatology (CEBD).³⁶ The CEBD systematically search for and map systematic reviews on atopic eczema by topics. Lists are updated monthly.

All listed reviews published since 2013 were screened in line with the key questions specified in each chapter. Our exclusion criteria were: Reviews lacking risk of bias assessment of the included studies, including mixed patient populations (e.g psoriasis and atopic eczema patients) and narrative reviews. Cochrane reviews and systematic reviews with GRADE assessments were preferred for their higher methodological quality. We provided the author groups with the identified publications, see Table 3.

Furthermore, to include the latest evidence in the different chapters, we updated the search of 11 selected systematic reviews and if needed, updated the search strategy (search date 30 June 2020). Author were provided with EndNote files.

Lastly, for nine systematic reviews identified on complementary medicine, psychosomatic counselling and educational interventions one methodologist assessed the quality of the reviews using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR-2) checklist.

More detailed information about the above mentioned steps, such as the AMSTAR 2 evaluation results, are available upon request (euroguiderm(at)debm.de).

Developing background texts

The guideline coordinators (AW and CF) suggested which members of the GDG could develop which section of the guideline. The allocation of work was discussed and finalized during the first online meeting, see Table 5. All author groups received a chapter template and any systematic review identified via the CEBD website and updated search results, where applicable (Table 3).

TABLE 5: DISTRIBUTION OF TASKS

Chapter(s)/topic(s)	Authors
Introduction	Andreas Wollenberg, Carsten Flohr
Methods	Corinna Dressler, Maria Kinberger and Carsten Flohr
AE management from a patient's perspective	Antje-Henriette Fink-Wagner, Magali Redding and Bernd Arents
General measures and avoidance strategies	Eva Maria Rehbinder, Krisztián Gáspár and Thomas Werfel
Basic emollient treatment, Bathing	Eva Maria Rehbinder, Bernd Arents, Jacek Szepietowski and Johannes Ring

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Dietary intervention	Charlotte Moertz, Helen Brough, Johannes Ring and Thomas Werfel,
Topical anti-inflammatory therapy	Nora Aszodi, Giampiero Girolomoni and Thomas Bieber
Phototherapy	Louise Gerbens and Piergiacomo Calzavara-Pinton,
Anti-pruritic therapy	Esther Serra-Baldrich, Jacek Szepietowski and Uwe Gieler
Antimicrobial therapy	Eva Maria Rehbinder, Nicole Fosse, and Sebastián Barbarot,
Introduction to systemic therapies	Mette Deleuran and Andreas Wollenberg,
Immunosuppressive treatment (CyA, Steroids, MTX, AZA, MMF)	Dagmar Simon, Mariateresa Rossi and Uffe Nygaard
JAK Inhibitors	Carsten Flohr, Antonio Torello and Stamatis Gregoriou
Biologics	Mariateresa Rossi and Mette Deleuran
Other systemic treatment	Dagmar Simon, Piergiacomo Calzavara-Pinton and Stamatis Grigoriou,
Allergen-specific immunotherapy	Esther Serra-Baldrich, Mariateresa Rossi and Krisztián Gáspár ,
Complementary medicine	Charlotte Moertz, Esther Serra-Baldrich and Mariateresa Rossi,
Psychosomatic counselling	Zsuzsanna Zsófia Szalai, Stéphanie Christen-Zäch, Sebastián Barbarot and Uwe Gieler (Group chapter)
Educational interventions	
Considerations for pregnancy	Andreas Wollenberg and Sebastián Barbarot,
Considerations for pediatric and adolescent patients	Magali Redding, Stéphanie Christen-Zäch, Zsuzsanna Zsófia Szalai, Antonio Torrelo and Krisztián Gáspár,
Occupational aspects	Esther Serra-Baldrich, Louise Gerbens and Uffe Nygaard

The co-authors prepared a draft chapter(s) including recommendations, which was subsequently reviewed and commented on by the EuroGuiDerm team and by at least one of the coordinators. Thereafter the co-authors revised the drafts where appropriate.

Developing recommendations and the consensus process

In accordance with the EuroGuiDerm Manual, we used phrasing suggested by the GRADE Working Group to standardize the wording of all recommendations³⁷, Table 6. Recommendations and texts were discussed and voted upon until a majority of more than 50% agreed.

TABLE 6: WORDING OF RECOMMENDATIONS³⁸⁻⁴¹

Strength	Wording	Symbols	Implications
<u>Strong</u> recommendation <u>for</u> the use of an intervention	'We recommend . ..'		We believe that all or almost all informed people would make that choice. Clinicians will have to spend less time on the process of decision-making, and may devote that time to overcome barriers to implementation and adherence. In most clinical situations, the recommendation may be adopted as a policy.
<u>Weak</u> recommendation <u>for</u>	'We suggest . . .'		We believe that most informed people would make that choice, but a substantial number would not. Clinicians and health care providers will need to

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

the use of an intervention			devote more time on the process of shared decision-making. Policy makers will have to involve many stakeholders and policy making requires substantial debate.
No recommendation with respect to an intervention	'We cannot make a recommendation with respect to . . .'	0	At the moment, a recommendation in favour or against an intervention cannot be made due to certain reasons (e.g. no reliable evidence data available, conflicting outcomes, etc.)
Weak recommendation against the use of an intervention	'We suggest against . . .'	↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
Strong recommendation against the use of an intervention	'We recommend against . . .'	↓↓	We believe that all or almost all informed people would make a choice against that intervention. This recommendation can be adopted as a policy in most clinical situations.

Online pre-voting

Between November 2020 and June 2021, a total of 8 online pre-votings took place to (a) familiarise the group with all draft recommendations and the chapter texts, to (b) collect feedback from the entire group and (c) to collect a vote on the recommendations. For the online pre-voting we used the tool LimeSurvey. While completing the survey, the answers and comments of the others were not visible to those working through the survey.

Each chapter was presented to all members of the guideline development group. Each member had the opportunity to agree or disagree with the draft text. In case of disagreement, the experts had the opportunity to comment or to suggest changes. All comments were reviewed by the two coordinators and all feedback was sent to the entire group.

The GDG members also voted on the draft recommendations and were specifically asked whether they agree or disagree with the strength and the wording of the recommendation(s). In case of disagreement, again, alternative suggestions and comments could be submitted. All members of the GDG were eligible to vote regardless of whether they declared any personal-financial interest. However, when calculating the strength of consensus on any recommendation pertaining to systemic treatment, we did not take the votes of those with person-financial interests into account. Although the EuroGuiDerm team could see how each person voted on the recommendations, this was never shared with the GDG. Submitted comments and suggestions were shared with the group. These were not anonymised.

The results and feedback from the online survey were then presented to the experts in the consensus conferences. If the coordinators or the co-authors, who had developed the drafts, had adjusted the recommendations based on the survey results, the changes were presented to the experts transparently.

Consensus conferences

Four online consensus conferences took place on 8 December 2020, 18 March 2021, 20 May 2021 and 22 July 2021. Alexander Nast, certified guideline facilitator, managed the process.

We used the nominal group technique⁴²: Alexander Nast first presented the anonymised results, comments and any suggested changes from the pre-voting survey.

He then opened the floor for discussion. Benefits, harms, processes and procedures were extensively discussed. After the discussion, the final voting took place. The experts could 'agree', 'disagree' or 'abstain' for each vote. If 100% agreement was achieved in the prevoting and there was no need for further discussion, the result from the prevoting was adopted instead of another vote.

During the first session on 8 December 2020, the virtual 'hand raising' function was used for the voting. In each of the later sessions, we used the addin *Forms*. This allowed for anonymous voting. Experts who had declared personal financial interests were not allowed to vote on any recommendation pertaining to systemic treatment.


Upadacitinib was licensed after the last conference, hence we used the tool Limey survey to facilitate an online vote. 8 of 15 experts voted for strong recommendations, 6 for a weak recommendation and 1 was against including any recommendation.

In the guideline itself, the strength of the consensus reached for each recommendation is reported as shown in Table 7.

TABLE 7: STRENGTH OF CONSENSUS

100 % consensus	100% agreement	
Strong consensus	Agreement of >95% - < 100% participants	
Consensus	Agreement of >75-95% participants	
Agreement of the majority	Agreement of >50-75% participants	

The recommendations are presented throughout this guideline as displayed below: alongside the wording of the recommendations the arrow(s) and color indicate the direction and the strength of each recommendation. The rate of agreement (consensus strength) is also displayed as the actual percentage and in form of a pie chart. For all systemic drugs, we added the standard dosages, separately for adults and children (European Medical Agency). Additionally, the certainty of evidence was added where applicable (bold – significant difference).

We suggest using azathioprine in AE patients who are candidates for systemic treatment.	↑	>75%  (14/15)
--	---	---

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

		Evidence and consensus based, see Evidence Report
azathioprine: off licence; commonly used dosage adults: 1-3 mg/kg per day children: 1-3 mg/kg per day Certainty of evidence ^{43,44} : Short term (8-16 weeks) vs placebo (NMA medications used in clinical practice or likely to be approved soon) ⊕⊕⊕○ MODERATE for standardized mean difference change in signs ⊕⊕○○ LOW for standardized mean difference QoL, itch <i>For azathioprine versus other drugs, see Evidence Report</i>		

For each recommendation that is evidence-based, we added the certainty of the evidence when compared to placebo (see also Figure 1).

High ⊕⊕⊕⊕: we are **very confident** that the true effect lies close to that of the estimate of the effect.
Medium ⊕⊕⊕○: we are **moderately confident** in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low ⊕⊕○○: our **confidence in the effect estimate is limited: The true effect may be substantially different** from the estimate of the effect.
Very low ⊕○○○: we have **very little confidence** in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

FIGURE 1: DEFINITIONS OF “CERTAINTY OF EVIDENCE”⁴⁵

Internal and external review

Internal review:

The guideline document and the methods & evidence report were sent to all members of the guideline development group. In addition to the general review of all three documents, each member of the guideline development group was explicitly assigned several chapters of the guideline or the evidence or methods report for critical review. These were chapters that the reviewers had not worked on themselves. Each chapter was reviewed in this way by at least two members of the guideline development group. After the review phase (16.08.2021 – 13.09.2022) all comments were combined in an word documents by the EuroGuiDerm Team. Editorial comments were directly resolved by the EuroGuiDerm Team. All other comments were sent to the coordinators AW and CF to be resolved. All changes to the guideline and the evidence and methods reports were made using the ‘track changes’ function. All reviewers received feedback to their comments alongside the GL and the evidence report and methods report where all changes resulting from the commenting phase are clearly visible. An anonymised version of all comments, feedback and action taken are available from euroguiderm@debm.de.

External review:

The guideline document, the methods report and the evidence report as well as the review commenting form were sent to: EDF Board, all supporting societies and pharmaceutical companies. After the review phase (03.11.2021 – 24.11.2021) all comments from the reviewer were combined in an word documents. Editorial comments were resolved by the EuroGuiDerm Team. All other comments were sent to the coordinators AW and CF to be resolved. All changes to the guideline and the evidence and methods reports were made using the “track changes” function. All reviewers received feedback to their comments alongside the GL and the evidence report and methods report where all changes resulting from the commenting phase are clearly visible. An anonymised version of all comments, feedback and action taken are available from euoguiderm@debm.de.

Dissemination and Implementation

To foster the implementation of the guideline into clinical practice, we developed visual aids (stepped care plans) and summary tables

We developed a dissemination and implementation plan, see Table 8.

Barriers and facilitators to implementation/application**Quality standards and monitoring indicators**

Over the two years following the publication of the EuroGuiDerm guideline on EDF website we will assess:

- Number of accesses and/or downloads from the EDF website
- Number of countries which adopted the guideline (translated the guideline as is, without change of content) by European countries, regions and non-European countries
- Number of countries which adapted the guideline (used parts of the guideline, or some recommendations) by European countries, regions and non-European countries

Evaluation Methods

Monitoring and evaluation is to be done at the national level.

- Change in practice performance
- Change in health outcomes
- Change in end-user knowledge and understanding

Patient-perspective and needs

Two patient representatives and one parent representative from the Eczema Outreach Support were part of the GDG. All three representatives participated in the pre-votings and all consensus meetings; they had one vote each. The patient representatives developed a chapter on the patient's perspective, which is part of the main guideline. The other members of the group had no say in the content of this chapter.

In addition, we considered the available evidence on patient's and other stakeholder's needs, which we present as part of the evidence-to-decision framework (see evidence report).

Strength and Limitations

The GDG members – representing 12 countries - contributed a variety of issues to the discussions around, for example, about the availabilities of drugs, on local clinical practice and national guidelines.

We pursued a rigorous policy on conflicts of interests, which were all pre-declared. Over 50% of all GDG members did not have a CoI. Furthermore, experts with personal-financial interests were not allowed to vote on the recommendations for systemic treatment.

We used the living systematic review and network meta-analysis by Drucker et al.²¹ as evidence base. The coordinator (CF) of the guideline is involved in the conduct of the review, where rigorous systematic methods were used. A protocol had been published.⁴⁶ We developed an evidence-to-decision framework for short term and long-term treatment, see evidence report.

Furthermore, we supported the co-authors, who developed the chapters other than those on systemic treatment, with systematic literature searches and focused screening, see Table 3.

For some chapters, such as the chapter on complementary medicine or on allergen specific immunotherapy, scarce evidence or only (very) low certainty evidence was available. For the complementary medicine chapter, we provided an AMSTAR 2⁴⁷ assessment of the available systematic reviews.

Due to the numerous chapters of this guideline, we conducted eight online pre-voting survey, and four consensus conferences took place. Although this meant that the duration of the development of the guideline was significantly longer, all co-authors did work through every chapter one by one. There was enough time to thoroughly discuss each chapter and all recommendations.

We only conducted very little background research on cost and economic considerations when developing the evidence-to-decision frameworks. Due to the different health care systems and the local/national requirements, no further consideration was given to costs. Although the European Medical Agency centrally approves drugs in Europe, there may be specific restrictions to use that differ by country. Facilitators and barriers to implementation need to be considered locally. This European guideline is developed in a format that lends itself to local adoption or adaptation.

Update and Methods

The GDG will review the evidence summarized by Drucker et al.²¹ every 18 months or when new treatments become available as part of a living EDF guideline on systemic therapies for atopic eczema.

The guideline subcommittee will also consider important clinical questions and review all consensus-based chapters every 5 years.

This process and updates will be available on the EDF website and communicated through appropriate channels.

Living Update 2022

The first update of the guideline was initiated to include abrocitinib in the guideline. Abrocitinib was approved by the EMA after the last consensus conference, which is why there was no recommendation for it in the old guideline. In addition, an update of the network meta-analysis by Drucker et al. has been published in March 2022.⁴³

The updated data from the network meta-analysis from March 2022 were summarised in an updated evidence report and provided to the members of the GDG. Subsequently, an online survey via LimeSurvey was created for the update. In this survey, the members of the GDG were consecutively presented with all the recommendations of the systemic therapy chapter from the old version. The members of the GDG then had to vote on whether they still agreed with each recommendation based on the new evidence. In the case of a rejection of the recommendation, the members were asked to make new suggestions. In addition, a new recommendation on abrocitinib, previously drafted by the coordinators AW und CF, was voted on in the survey. Furthermore, slightly modified recommendations from the chapter on pregnancy and breastfeeding, in which abrocitinib or tralokinumab were added, were newly voted on. In addition to the recommendations, the survey also voted on updated stepped-care plans for adults and for children and adolescents, which include the newly approved drug abrocitinib. The drafts for these were previously prepared by the EuroGuiDerm team together with the coordinators AW and CF. Drafts of the updated tables on general recommendations for systemic drugs for adult AE patients and on general recommendations for systemic drugs for special AE patient populations, in which abrocitinib was included, were also voted on in the online survey.

All members of the GDG received access to the online survey and were able to complete it between 11 August 2022 and 18 September 2022. In this way, a general opinion could first be obtained for all recommendations. Subsequently, an evaluation was carried out, whereby only those members of the guideline development group who had indicated that they had no COIs were taken into account. The latter was the evaluation that was finally counted.

After the survey was completed, all comments and suggestions were summarised and submitted to the coordinators AW and CF. As there were high approval rates in all votes, no further adjustments were made to the recommendations. Two minor editorial changes were made to the tables. These were presented to the guideline development group. However, no one objected to these changes, so they were included in the tables.

For the first update in 2022, the group comprised experts from twelve countries. Eleven experts (40.7%) declared personal financial conflicts of interest, see below.

Title	First name	Last name	Personal- financial conflicts of interest
	Bernd	Arents	None
Dr.	Nora	Aszodi	None
Prof. Dr.	Sebastien	Barbarot	S Barbarot is an investigator or speaker for Almirall, Sanofi-Genzyme, Abbvie, Leo-Pharma, Pfizer, Eli Lilly
Prof. Dr.	Thomas	Bieber	T. Bieber was speaker and/or consultant and/or Investigator for AbbVie, Affibody, Almirall, AnaptysBio, Arena, Asana Biosciences, ASLAN pharma, Bayer

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

			Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Dermavant, DIECE Therapeutics, Domain Therapeutics, EQRx, Galderma, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L'Oréal, MSD, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB. He is founder and chairman of the board of the non-profit biotech "Davos Biosciences".
Dr.	Helen A.	Brough	None
Prof. Dr.	Piergiacomo	Calzavara Pinton	Speaker at congresses for LEO, Sanofi, Abbvie
Dr.	Stéphanie	Christen-Zäch	None
Dr.	Mette	Deleuran	Advisory board member, safety board member and/or speaker for the following companies: La Roche Posay, Pierre Fabre, Sanofi-Genzyme, Regeneron, Leo Pharma, ARENA Pharmaceuticals, ASLAN Pharmaceuticals, Kymab, Incyte, AbbVie, and Lilly
Prof. Dr.	Carsten	Flohr	None
Dr.	Nicole	Fosse	None
Dr.	Krisztián	Gáspár	None
Dr.	Louise	Gerbens	None
Prof. Dr.	Uwe	Gieler	None
Prof. Dr.	Giampiero	Girolomoni	Dr. Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Fresenius Kabi, Galderma, Genzyme, Leo Pharma, Novartis, Pfizer, Regeneron, Samsung bioepis, Sanofi and UCB.
Prof. Dr.	Stamatis	Gregoriou	None
Prof. Dr.	Charlotte	Mortz	None
MD PhD	Uffe	Nygaard	None
MD PhD	Eva Maria	Rehbinder	None
Prof. Dr.	Johannes	Ring	Honoraria as speaker or advisory board member: AbbVie, Allergika, ALK abello, Bencard, Galderma, Leo, Pfizer, Sanofi, viatris
Dr.	Mariateresa	Rossi	None
	Christine	Roxburgh	None
Dr.	Esther	Serra-Baldrich	None
Prof. Dr.	Dagmar	Simon	None

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Prof. Dr.	Zsuzsanna	Szalai	Sanofi, AbbVie
Prof. Dr.	Jacek C.	Szepietowski	Advisory Board member/Consultant - Sanofi-Genzyme, Pfizer Speaker - Abbvie, Sanofi-Genzyme, Pfizer Investigator - Regeneron, Abbvie, Pfizer
Dr.	Antonio	Torrelo	Investigator for Lilly, Galderma, Pfizer Advisor and/or lecturer for Lilly, Sanofi, Pfizer, Novartis, Pierre Fabre
Prof. Dr.	Thomas	Werfel	TW has received institutional grants or personal fees for lectures or advisory boards from AbbVie, Almirall, Eli Lilly, Galderma, Janssen/JNJ, Leo Pharma, Novartis, Pfizer, Regeneron/Sanofi.
Prof. Dr. med. Dr. h.c.	Andreas	Wollenberg	I have received honoraria for attending advisory boards from pharmaceutical companies producing biologics and small molecules and topical drugs for treatment of atopic dermatitis (e.g. Abbvie, Aileens, Almirall, Amgen, BMS, Galapagos, Galderma, GSK, Janssen, Leo Pharma, Eli Lilly, MedImmune, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi-Aventis).

Living Update 2024

The second update of the guideline was initiated to include lebrikizumab in the guideline. Lebrikizumab was approved by the EMA after the last update of the guideline, which is why there was no recommendation for it in the old guideline. In addition, baricitinib received an extension of approval for use in children and adolescents aged 2 years and older and abrocitinib for use in adolescents aged 12 years and older. These aspects were also integrated into the guideline update.

Furthermore, an update of the network meta-analysis by Drucker et al. was published in July 2024.⁴⁸ The updated data from the network meta-analysis from July 2024 were summarised in an updated evidence report and provided to the members of the GDG. Subsequently, an online survey via LimeSurvey was created for the update.

In this survey, the members of the GDG were shown all the changes in the background texts (which had previously been prepared by the coordinators AW and CF) one after the other. The members of the GDG were asked in each case whether they agreed with, abstained from or rejected the changes. In the event of abstention or rejection, the members of the GDG had the opportunity to explain their decision and/or submit counter-proposals.

The new recommendation on lebrikizumab, which had previously been pre-formulated by the coordinators AW and CF, was voted on in the same way. There was also a new vote on slightly modified recommendations from the chapter on pregnancy and breastfeeding, in which lebrikizumab was added.

In addition, the survey also included votes on updated stepped-care plans for adults and for children and adolescents. The drafts for these were previously prepared by the EuroGuiDerm team together with the coordinators AW and CF.

Drafts of the updated tables on general recommendations for systemic drugs for adult AE patients and on general recommendations for systemic drugs for special AE patient populations, were also voted on in the online survey.

All members of the GDG received access to the online survey and were able to complete it between 21 July 2024 and 11 August 2024. In this way, a general opinion could first be obtained for all recommendations. Subsequently, an evaluation was carried out, whereby only those members of the guideline development group who had indicated that they had no COIs were taken into account. The latter was the evaluation that was finally counted.

After the survey was completed, all comments and suggestions were summarised and submitted to the coordinators AW and CF. As there were high approval rates in all votes, no further adjustments were made to the recommendations. Minor editorial changes were made to the tables, stepped-care plans and background texts. These were presented to the guideline development group. However, no one objected to these changes, so they were included.

For the second update in 2024, the group comprised experts from twelve countries. Ten experts (35,7%) declared personal financial conflicts of interest, see below.

Title	First name	Last name	Personal- financial conflicts of interest
	Bernd	Arents	None

Dr.	Nora	Aszodi	None
Prof. Dr.	Sebastien	Barbarot	S Barbarot is an investigator or speaker for Astrazeneca, Almirall, Sanofi-Genzyme, Abbvie, Galderma, Alexion, Novartis,
Prof. Dr.	Thomas	Bieber	T Bieber has been/currently a consultant for numerous pharmaceutical companies with MP in this indication
Dr.	Helen A.	Brough	None
Prof. Dr.	Piergiacomo	Calzavara Pinton	None
Dr.	Stéphanie	Christen-Zäch	None
Dr.	Mette	Deleuran	Advisor and/or speaker for the following companies:AbbVie, Almirall, Apogee, Eli Lilly, Galderma, Incyte, Kymab, La Roche Posay, Leo Pharma, Medscape, Mustela, Numab, Pfizer, Pierre Fabre, Regeneron, Sanofi, UCB, Union Therapeutics.
Prof. Dr.	Carsten	Flohr	In the past 3 years: Personal payments for educational activities related to atopic eczema, sponsored by Sanofi, Almirall,
Dr.	Nicole	Fosse	None
Dr.	Krisztián	Gáspár	None
Dr.	Louise	Gerbens	None
Prof. Dr.	Uwe	Gieler	None
Prof. Dr.	Giampiero	Girolomoni	Personal fees for speaking at sponsored meetings from Abbvie, Almirall, Bristol Myers Squibb, Pfizer, Eli Lilly, Boehringer
Prof. Dr.	Stamatis	Gregoriou	None
	Holland	Suzi	None
Prof. Dr.	Charlotte	Mortz	None
MD PhD	Uffe	Nygaard	None
MD PhD	Eva Maria	Rehbinder	None
Prof. Dr.	Johannes	Ring	Honoraria for lectures and consulting for the following companies:AbbVie, Sanofi, Allergika, Pfizer, Viatris
Dr.	Mariateresa	Rossi	None
Dr.	Esther	Serra-Baldrich	None
Prof. Dr.	Dagmar	Simon	None

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Prof. Dr.	Zsuzsanna	Szalai	None
Prof. Dr.	Jacek C.	Szepietowski	Advisory Board Member of Galderma, Leo Pharma, Novartis, Sanofi-Genzyme, Pfizer and UCB. Speaker for Abbvie, Almirall, Janssen-Cilag, Eli-Lilly, Leo-Pharma, Pfizer, Sanofi-Genzyme, UCB. Investigator for Abbvie, BMS, Galderma, Incyte, Pfizer, UCB, Regeneron
Dr.	Antonio	Torrelo	"Viatris - Advisory boards, lecturing Pierre Fabre - Lecturing Sanofi - Lecturing Eli Lilly - Advisory boards, lecturing"
Prof. Dr.	Thomas	Werfel	T Werfel has performed consultancies for Abbvie, Almirall, Galderma, LEO, Lilly, Novartis, Pfizer, Sanofi-Regeneron and has lectured at educational events sponsored by Abbvie, Almirall, Galderma, LEO Pharma, Lilly, Pfizer, Sanofi and Novartis
Prof. Dr. med. Dr. h.c.	Andreas	Wollenberg	A Wollenberg has received grants, personal fees or nonfinancial support from AbbVie, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DKSH, Eli Lilly, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, Leo Pharma, L'Oreal, Maruho, MedImmune, Merck, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis and UCB.

The updated guideline document (chapters on systemic treatment, chapter on pregnancy, breastfeeding, and family planning, the stepped-care plans and the drug tables) were sent to all members of the guideline development group for internal review. After the review phase all comments were combined in a word documents by the EuroGuiDerm Team. Editorial comments were directly resolved by the EuroGuiDerm Team. All other comments were sent to the coordinators AW and CF to be resolved. All changes to the guideline were made using the 'track changes' function. All reviewers received feedback to their comments. Changes resulting from the commenting phase were clearly visible. An anonymised version of all comments, feedback and action taken are available from euroguiderm@debm.de.

Afterwards the guideline document, the methods report and the evidence report were sent to: EDF Board, all supporting societies and pharmaceutical companies. After the review phase all comments from the reviewer were combined in a word documents. Editorial comments were resolved by the EuroGuiDerm Team. All other comments were sent to the coordinators AW and CF to be resolved. All changes to the guideline and the evidence and methods reports were made using the "track changes" function. All reviewers received feedback to their comments alongside the GL and the evidence report and methods report where all changes resulting from the commenting phase are clearly visible. An anonymised version of all comments, feedback and action taken are available from euroguiderm@debm.de.

Living Update 2025

The third update of the guideline was initiated to incorporate nemolizumab. As nemolizumab received EMA approval after the previous guideline update, it had not yet been addressed in earlier versions. In addition, the guideline group decided to include guidance on vaccination prior to initiating systemic therapy and during ongoing systemic treatment, as well as guidance on switching systemic therapies and adjusting treatment frequency and intervals.

Furthermore, an update of the network meta-analysis by Drucker et al. was published in May 2025.⁴⁹ The updated data from the network meta-analysis from May 2025 were summarised in an updated evidence report.

The clinical guideline coordinators, Andreas Wollenberg and Carsten Flohr, prepared new guideline chapters and revised the existing chapters on systemic therapy and therapy during pregnancy and breastfeeding. These newly prepared and updated texts, along with the corresponding recommendation texts, were presented to the GDG in an online survey.

In this survey, the members of the GDG were shown all the changes in the background texts and the recommendations one after the other. The members of the GDG were asked in each case whether they agreed with, abstained from or rejected the changes. In the event of abstention or rejection, the members of the GDG had the opportunity to explain their decision and/or submit counter-proposals. In addition, the survey also included votes on all recommendations on systemic treatment, the updated stepped-care plans for adults and for children and adolescents. Drafts of the updated tables on general recommendations for systemic drugs for adult AE patients and on general recommendations for systemic drugs for special AE patient populations, were also voted on in the online survey. All members of the GDG received access to the online survey and were able to complete it between 1 September 2025 and 17 September 2025. In this way, a general opinion could first be obtained for all recommendations. Subsequently, an evaluation was carried out, whereby only those members of the guideline development group who had indicated that they had no COIs were taken into account. The latter was the evaluation that was finally counted.

All recommendations that did not achieve full approval in the online vote, as well as background-text changes requiring further discussion, were reconsidered during an online consensus conference on 30 September. The process was moderated by Ricardo N. Werner, a certified guideline facilitator, using the nominal group technique. He first presented the anonymised results, comments, and suggested modifications from the pre-voting survey, then opened the floor for discussion. Benefits, harms, processes, and procedures were discussed in detail. Final voting followed, with experts choosing to agree, disagree, or abstain for each recommendation. All GDG members were asked to participate. As before, the definitive evaluation included only the votes of members without COIs.

For the second update in 2025, the group comprised experts from twelve countries. Thirteen experts (46.4%) declared personal financial conflicts of interest, see below.

Title	First name	Last name	Relevant personal- financial conflicts of interest
	Bernd	Arents	None
Dr.	Nora	Aszodi	None

Prof. Dr.	Sebastien	Barbarot	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Thomas	Bieber	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi
Dr.	Helen A.	Brough	Leo
Prof. Dr.	Piergiacomo	Calzavara Pinton	None
Dr.	Stéphanie	Christen-Zäch	None
Dr.	Mette	Deleuran	Abbvie, Almirall, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Carsten	Flohr	Almirall, Leo, Pfizer, Sanofi
Dr.	Nicole	Fosse	None
Dr.	Krisztián	Gáspár	Abbvie, Sanofi
Dr.	Louise	Gerbens	None
Prof. Dr.	Uwe	Gieler	None
Prof. Dr.	Giampiero	Girolomoni	Abbvie, Almirall, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Stamatis	Gregoriou	None
	Holland	Suzi	None
Prof. Dr.	Charlotte	Mortz	None
MD PhD	Uffe	Nygaard	None
MD PhD	Eva Maria	Rehbinder	None
Prof. Dr. Dr.	Johannes	Ring	Abbvie, Sanofi
Dr.	Mariateresa	Rossi	None
Dr.	Esther	Serra-Baldrich	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Dagmar	Simon	None
Prof. Dr.	Zsuzsanna	Szalai	None
Prof. Dr.	Jacek C.	Szepietowski	Almirall, Leo, Pfizer, Sanofi
Dr.	Antonio	Torrelo	Abbvie, Lilly, Pfizer, Sanofi

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

Prof. Dr.	Thomas	Werfel	Abbvie, Almirall, Galderma, Sanofi
Prof. Dr. med. Dr. h.c.	Andreas	Wollenberg	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi

The updated guideline document (chapters on systemic treatment, chapter on pregnancy, breastfeeding, and family planning, the stepped-care plans and the drug tables) were send to all members of the guideline development group for internal review. After the review phase all comments were combined in a word documents by the EuroGuiDerm Team. Editorial comments were directly resolved by the EuroGuiDerm Team. All other comments were sent to the coordinators AW and CF to be resolved. All changes to the guideline were made using the `track changes`function. All reviewers received feedback to their comments. Changes resulting from the commenting phase were clearly visible. An anonymised version of all comments, feedback and action taken are available from euroguiderm@debm.de.

After the internal review the updated guideline chapters, the Evidence Report and the Methods Report were send to: EDF Board, all supporting societies and pharmaceutical companies for external review. After the review phase all comments from the reviewer were combined in an word documents. Editorial comments were resolved by the EuroGuiDerm Team. All other comments were sent to the clinical coordinators AW and CF to be resolved. All changes to the guideline were made using the “track changes” function. All reviewers received feedback to their comments and all changes resulting from the commenting phase are clearly visible. An anonymised version of all comments, feedback and action taken are available from euroguiderm@debm.de

Methods Report	EuroGuiDerm Centre for Guideline Development
-----------------------	--

TABLE 8: DISSEMINATION PLAN

Audience	Responsible Subcommittee member(s)	Communication and/or implementation tools to be used	Time at which they are to be developed, piloted or to take place	Is EuroGuiDerm support needed, and if yes what kind of support?
Dermatology, General Medicine, Patients / Patient Organisations, Research	A Wollenberg, C Flohr	Slide set (power point)	After external review	No
Dermatology, General Medicine, Patients / Patient Organisations, Research	EuroGuiDerm	Website	After external review	EuroGuiDerm Team to organize the website, layout etc
Dermatology, General Medicine, Research	A Wollenberg, C Flohr, EuroGuiDerm	Journal publication	Submission at the same time as the external review	Assistance with submission process
Dermatology, General Medicine, Patients / Patient Organisations, Research	EuroGuiDerm Team	Twitter, EuroGuiDerm newsletter	Once the website is running, each time the publication is early online	EuroGuiDerm Team

References

1. Nankervis H, Pynn EV, Boyle RJ, et al. House dust mite reduction and avoidance measures for treating eczema. *Cochrane Database Syst Rev*. Jan 19 2015;1:Cd008426. doi:10.1002/14651858.CD008426.pub2
2. Kramer U, Behrendt H. [Air pollution and atopic eczema : Systematic review of findings from environmental epidemiological studies]. *Hautarzt*. Mar 2019;70(3):169–184. Luftverschmutzung und atopisches Ekzem : Systematisches Review der Erkenntnisse aus umweltepidemiologischen Studien. doi:10.1007/s00105-018-4330-3
3. Kim A, Silverberg JL. A systematic review of vigorous physical activity in eczema. *Br J Dermatol*. Mar 2016;174(3):660–2. doi:10.1111/bjd.14179
4. Jaros J, Wilson C, Shi VY. Fabric Selection in Atopic Dermatitis: An Evidence-Based Review. *Am J Clin Dermatol*. Aug 2020;21(4):467–482. doi:10.1007/s40257-020-00516-0
5. Chan CWH, Law BMH, Liu YH, et al. The Association between Maternal Stress and Childhood Eczema: A Systematic Review. *Int J Environ Res Public Health*. Feb 25 2018;15(3)doi:10.3390/ijerph15030395
6. Flanigan C, Sheikh A, DunnGalvin A, Brew BK, Almqvist C, Nwaru BI. Prenatal maternal psychosocial stress and offspring's asthma and allergic disease: A systematic review and meta-analysis. *Clin Exp Allergy*. Apr 2018;48(4):403–414. doi:10.1111/cea.13091
7. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. *Cochrane Database Syst Rev*. Feb 6 2017;2:Cd012119. doi:10.1002/14651858.CD012119.pub2
8. González-López G, Ceballos-Rodríguez RM, González-López JJ, Feito Rodríguez M, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol*. Sep 2017;177(3):688–695. doi:10.1111/bjd.15165
9. Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et al. Probiotics for treating eczema. *Cochrane Database Syst Rev*. Nov 21 2018;11(11):Cd006135. doi:10.1002/14651858.CD006135.pub3
10. Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. *Cochrane Database Syst Rev*. Apr 30 2013;(4):Cd004416. doi:10.1002/14651858.CD004416.pub2
11. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. *Cochrane Database Syst Rev*. Feb 15 2012;(2):Cd005205. doi:10.1002/14651858.CD005205.pub3
12. Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. *Cochrane Database Syst Rev*. Jan 23 2008;2008(1):Cd005203. doi:10.1002/14651858.CD005203.pub2
13. Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic Review and Meta-analysis Comparing Topical Corticosteroids With Vehicle/Moisturizer in Childhood Atopic Dermatitis. *J Pediatr Nurs*. Jul – Aug 2019;47:36–43. doi:10.1016/j.pedn.2019.03.018
14. Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. *Postępy dermatologii i alergologii*. Dec 2019;36(6):752–759. doi:10.5114/ada.2019.91425
15. Fahrback K, Tarpey J, Washington EB, et al. Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis. *Dermatol Ther (Heidelb)*. Aug 2020;10(4):681–694. doi:10.1007/s13555-020-00389-5
16. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. *Cochrane Database Syst Rev*. Jul 1 2015;2015(7):Cd009864. doi:10.1002/14651858.CD009864.pub2

17. Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. *Br J Dermatol*. Mar 2014;170(3):501–13. doi:10.1111/bjd.12645
18. Matteredne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. *Cochrane Database Syst Rev*. Jan 22 2019;1(1):Cd012167. doi:10.1002/14651858.CD012167.pub2
19. George SM, Karanovic S, Harrison DA, et al. Interventions to reduce Staphylococcus aureus in the management of eczema. *Cochrane Database Syst Rev*. Oct 29 2019;2019(10)doi:10.1002/14651858.CD003871.pub3
20. Tsakok T, Schulenburg H, Smith C, Till S, Flohr C. The Role of Yeast in Atopic Dermatitis Revisited: a Critical Appraisal. *Current Dermatology Reports*. 2015/12/01 2015;4(4):228–240. doi:10.1007/s13671-015-0123-4
21. Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. *JAMA Dermatol*. Jun 1 2020;156(6):659–667. doi:10.1001/jamadermatol.2020.0796
22. Ferguson L, Futamura M, Vakirlis E, et al. Leukotriene receptor antagonists for eczema. *Cochrane Database Syst Rev*. Oct 21 2018;10(10):Cd011224. doi:10.1002/14651858.CD011224.pub2
23. Tam HH, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. *Allergy*. Sep 2016;71(9):1345–56. doi:10.1111/all.12932
24. Gu S, Yang AW, Li CG, Lu C, Xue CC. Topical application of Chinese herbal medicine for atopic eczema: a systematic review with a meta-analysis. *Dermatology*. 2014;228(4):294–302. doi:10.1159/000360526
25. Gu S, Yang AW, Xue CC, et al. Chinese herbal medicine for atopic eczema. *Cochrane Database Syst Rev*. Sep 10 2013;(9):Cd008642. doi:10.1002/14651858.CD008642.pub2
26. Fieten KB, Weststrate AC, van Zuuren EJ, Bruijnzeel-Koomen CA, Pasmans SG. Alpine climate treatment of atopic dermatitis: a systematic review. *Allergy*. Jan 2015;70(1):12–25. doi:10.1111/all.12514
27. Jiao R, Yang Z, Wang Y, Zhou J, Zeng Y, Liu Z. The effectiveness and safety of acupuncture for patients with atopic eczema: a systematic review and meta-analysis. *Acupunct Med*. Feb 2020;38(1):3–14. doi:10.1177/0964528419871058
28. Lu CL, Liu XH, Stub T, et al. Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials. *BMC Complement Altern Med*. Sep 26 2018;18(1):260. doi:10.1186/s12906-018-2306-6
29. Kwon CY, Lee B, Kim S, Lee J, Park M, Kim N. Effectiveness and Safety of Herbal Medicine for Atopic Dermatitis: An Overview of Systematic Reviews. *Evid Based Complement Alternat Med*. 2020;2020:4140692. doi:10.1155/2020/4140692
30. Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. *Cochrane Database Syst Rev*. Jan 7 2014;(1):Cd004054. doi:10.1002/14651858.CD004054.pub3
31. Hashimoto K, Ogawa Y, Takeshima N, Furukawa TA. Psychological and Educational Interventions for Atopic Dermatitis in Adults: A Systematic Review and Meta-Analysis. *Behaviour Change*. 2017;34(1):48–65. doi:10.1017/bec.2017.4
32. Ridd MJ, King AJL, Le Roux E, Waldecker A, Huntley AL. Systematic review of self-management interventions for people with eczema. *Br J Dermatol*. Sep 2017;177(3):719–734. doi:10.1111/bjd.15601
33. Li Y, Han T, Li W, Li Y, Guo X, Zheng L. Efficacy of health education on treatment of children with atopic dermatitis: a meta-analysis of randomized controlled trials. *Arch Dermatol Res*. Dec 2020;312(10):685–695. doi:10.1007/s00403-020-02060-7

34. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol*. Sep 2019;33(9):1644–1659. doi:10.1111/jdv.15709
35. Nørreslet LB, Ebbelhøj NE, Ellekilde Bonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life - a systematic review. *J Eur Acad Dermatol Venereol*. Jan 2018;32(1):23–38. doi:10.1111/jdv.14523
36. Centre of Evidence Based Dermatology (CEBD). Systematic reviews on eczema. Updated (last accessed 23 March 2020). Accessed 23 March, 2020.
<https://www.nottingham.ac.uk/research/groups/cebd/resources/eczema-systematic-reviews.aspx>
37. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology*. Apr 2011;64(4):383–94. doi:10.1016/j.jclinepi.2010.04.026
38. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *Journal of clinical epidemiology*. Apr 2011;64(4):380–2. doi:10.1016/j.jclinepi.2010.09.011
39. The GRADE Working Group. Accessed July 10, 2018. <http://www.gradeworkinggroup.org/>
40. Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. *J Eur Acad Dermatol Venereol*. Jan 2017;31(1):9–19. doi:10.1111/jdv.13995
41. Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. *J Eur Acad Dermatol Venereol*. Jan 2017;31(1):20–29. doi:10.1111/jdv.13957
42. German Association of the Scientific Medical Societies (AWMF) - Standing Guidelines Commission. *AWMF Guidance Manual and Rules for Guideline Development, 1st Edition 2012. English version*. 2012. <http://www.awmf.org/leitlinien/awmf-regelwerk.html>
43. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. *JAMA Dermatol*. May 1 2022;158(5):523–532. doi:10.1001/jamadermatol.2022.0455
44. Drucker AM. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta-analysis. 06.07.2022, <https://eczematherapies.com/research/>
45. Schünemann H, Brożek J, Guyatt G, Oxman A. Table 5.1 in GRADE handbook for Grading quality of evidence and strength of recommendations. 10.08.2021, Accessed 10.08.2021, <https://gdt.gradepro.org/app/handbook/handbook.html#h.9rdbelsnu4iy>
46. Drucker AM, Ellis A, Jabbar-Lopez Z, et al. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. *BMJ Open*. Aug 29 2018;8(8):e023061. doi:10.1136/bmjopen-2018-023061
47. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*. 2017;358:j4008. doi:10.1136/bmj.j4008
48. Drucker AM, Lam M, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. *JAMA Dermatol*. Sep 1 2024;160(9):936–944. doi:10.1001/jamadermatol.2024.2192
49. Drucker AM, Walwyn C, Chu C, et al. Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis. *Br J Dermatol*. Aug 18 2025;193(3):548–552. doi:10.1093/bjd/ljaf166

50. Harmonizing outcome measures for eczema (HOME). Core outcomes for trials. Accessed 16 March, 2020. <http://www.homeforeczema.org/research/index.aspx>
51. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol*. May 2018;32(5):657–682. doi:10.1111/jdv.14891
52. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol*. Jun 2018;32(6):850–878. doi:10.1111/jdv.14888
53. МоН (UA) - The State Expert Center МоН, Ukraine,,. Атопічний дерматит. Адаптована клінічна настанова, заснована на доказах [Atopic dermatitis. Adapted evidence-based guideline]. Jul 04 2016;
54. Lee JA, Choi J, Choi T-Y, et al. Clinical practice guidelines of Korean medicine on acupuncture and herbal medicine for atopic dermatitis: A GRADE approach. *European Journal of Integrative Medicine*. 2016/10/01/ 2016;8(5):854–860. doi:<https://doi.org/10.1016/j.eujim.2016.07.028>
55. C. C. Current Care Guidelines / the Finnish Medical Society Duodecim. Atooppinen ekseema [Atopic eczema]. Updated 19.09.2016. Accessed January 13, 2020. <https://www.kaypahoito.fi/hoi50077>
56. Johnston GA, Exton LS, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of contact dermatitis 2017. *Br J Dermatol*. Feb 2017;176(2):317–329. doi:10.1111/bjd.15239
57. Werfel T. et al. AWMF - Association of Scientific Medical Societies. Neurodermitis. S2e-LL (DDG). Guideline. Updated 30.09.2015. Accessed January 13, 2020. <http://www.awmf.org/leitlinien/detail/II/013-027.html>
58. Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F, Pigatto PDM. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). *Dermatol Ther*. Nov 2019;32(6):e13121. doi:10.1111/dth.13121
59. Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. *The Journal of dermatology*. Dec 2019;46(12):1053–1101. doi:10.1111/1346-8138.15090
60. Rajagopalan M, De A, Godse K, et al. Guidelines on Management of Atopic Dermatitis in India: An Evidence-Based Review and an Expert Consensus. *Indian journal of dermatology*. May–Jun 2019;64(3):166–181. doi:10.4103/ijd.IJD_683_18
61. Sidbury R, Kodama S. Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care. *Clin Dermatol*. Sep – Oct 2018;36(5):648–652. doi:10.1016/j.clindermatol.2018.05.008
62. Wong IY, Tsuyuki RT, Cresswell-Melville A, Doiron P, Drucker AM. Guidelines for the management of atopic dermatitis (eczema) for pharmacists. *Can Pharm J (Ott)*. Sep–Oct 2017;150(5):285–297. doi:10.1177/1715163517710958
63. Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. *Allergol Int*. Apr 2017;66(2):230–247. doi:10.1016/j.alit.2016.12.003
64. Nowicki R, Trzeciak M, Wilkowska A, et al. Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. *Postepy dermatologii i alergologii*. Aug 2015;32(4):239–49. doi:10.5114/pdia.2015.53319
65. Werfel T, Heratizadeh A, Aberer W, et al. S2k-Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] – Kurzversion. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*. 2016;14(1):92–106. doi:10.1111/ddg.140_12871
66. National Institute for Health and Care Excellence (NICE). Eczema overview. Accessed 16 March, 2020. <https://pathways.nice.org.uk/pathways/eczema>

67. LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. *Pediatric dermatology*. Jan 2019;36(1):36–65. doi:10.1111/pde.13678
68. Vermeulen FM, Gerbens LAA, Schmitt J, et al. The European TREATment of ATopic eczema Taskforce (TREAT) Survey; prescribing practices in Europe for phototherapy and systemic therapy in moderate-to-severe adult atopic eczema patients. *Br J Dermatol*. Feb 18 2020;doi:10.1111/bjd.18959
69. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *Journal of the European Academy of Dermatology and Venereology*. 2019;33(9):1644–1659. doi:10.1111/jdv.15709
70. Drucker AM, Ellis A, Jabbar-Lopez Z, et al. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. *BMJ Open*. Aug 29 2018;8(8):e023061. doi:10.1136/bmjopen-2018-023061
71. Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. *Journal of the American Academy of Dermatology*. Jul 2019;81(1):187–195. doi:10.1016/j.jaad.2019.03.037
72. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *J Eur Acad Dermatol Venereol*. May 2016;30(5):729–47. doi:10.1111/jdv.13599
73. Gutknecht M, Reinert R, Augustin M. Review of health economic analyses in atopic dermatitis: how diverse is the literature? *Expert review of pharmacoeconomics & outcomes research*. Apr 2019;19(2):127–145. doi:10.1080/14737167.2019.1549491
74. Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. *J Eur Acad Dermatol Venereol*. Jul 2019;33(7):1331–1340. doi:10.1111/jdv.15634

Appendices

Appendix 1: E-mail send to funding societies

Dear xxx

We thank xxxx for the support of the EDF – EuroGuiDerm Guidelines Center. A broad base for the funding is crucial for the project's success. As one of the supporting societies, we want to invite you to suggest members for the guidelines groups.

The **EuroGuiDerm Atopic Dermatitis Guideline** is now being updated.

We are looking for

1. An established expert to become a member of the guideline development group, who ***preferably has little or no conflicts of interests with the pharmaceutical industry***. We are looking for dermatologists with at least 10 years' experience as a consultant (or equivalent).
and possibly
2. A junior doctor, who does ***not have any conflicts of interests with the pharmaceutical industry*** and who is interested in getting involved in guideline development work. Must have at least 4 years of clinical experience in dermatology.

The nominated experts will be involved in writing the background texts, draft recommendations and vote on the final guideline. Systematic search and literature approval will be done by the EuroGuiDerm center.

The deadline for nominations is January 15th, 2020. Please send your suggestions, and for the junior doctors please also a CV to atopic-dermatitis@debm.de.

Lastly, if there are any specific issues or key points arising nationally which should be taken into account during the guideline development, please inform us as soon as possible.

With best regards

Alexander

For more information on EuroGuiDerm, please visit our website:
<https://www.edf.one/de/home/Guidelines/EDF---EuroGuiDerm.html>

Prof. Dr. med Alexander Nast
Consultant Dermatologist/Clinical lead
Director of EuroGuiDerm
Department of Dermatology, Venerology und Allergy
Charité - Universitätsmedizin Berlin
Charitéplatz 1
D - 10117 Berlin
Germany

Appendix 2: Scoping document of the EuroGuiDerm Atopic Dermatitis guideline

– created in April 2020

Update of the EuroGuiDerm Atopic Dermatitis (AD) guideline

SCOPING DOCUMENT

1. Planned methodological approach (guideline or consensus statement)

- EuroGuiDerm^a Guideline on the systemic treatment for atopic dermatitis
- EuroGuiDerm Consensus Statement on topical therapy, phototherapy and other treatment options for AD

2. Broadly defined scope population/region/setting/interventions/comparisons/outcomes

- Population: Patients (all ages, all genders) with atopic dermatitis (AD; syn. atopic eczema) of all severities. Including special circumstances: pregnancy and concomitant allergic disease.
- Region: Europe
- Setting: Dermatologists and allergists in clinical practice
- Interventions/treatment approaches :
 - Systemic anti-inflammatory treatment (*Table 9*)
 - General measure and avoidance strategies
 - Basic emollient therapy and bathing
 - Dietary intervention
 - Topical anti-inflammatory treatment (including pro-active treatments)
 - Phototherapy
 - Antimicrobial therapy
 - Complementary medicine
 - Psychosomatic counselling
 - Educational interventions

Table 9: Systemic anti-inflammatory treatments*

Conventional immunosuppressants	TH2-blockers	Anti-IL 31	Small molecules	Other
Azathioprine	Dupilumab	Nemolizumab	Apremilast	Alitretinoin
Cyclosporine	Tralokinumab		Abrocitinib	Adirforant

^a The EDF has launched in 2018 the European Centre for Guidelines Development EuroGuiDerm in collaboration with Prof. Alexander Nast from the Division of Evidence-Based Medicine, Department of Dermatology, Charité University, Berlin. More information can be found on the EDF website: <https://www.edf.one/home/Guidelines/Guideline-Methods-.html>

Methotrexate	Lebrikizumab		Baricitinib	Corticosteroids (oral, IV, IM)
Mycophenolate			Upadacitinib	

**Included are only those treatments deemed most relevant to clinical practice and those expected to get market authorization within the next ~ 1.5 years.*

- Comparisons: Direct, indirect and placebo.
- Outcomes: The Harmonising Outcome Measures for Eczema (HOME)⁵⁰ as well as the *European Dermatology Forum (EDF) atopic dermatitis guideline committee 2018*^{51,52} have both performed extensive exercises to determine essential outcomes in atopic dermatitis. It was deemed unnecessary to repeat this process for the update of the guideline.

The core outcomes for AD in a trial setting (HOME)^b or when it comes to the choice of therapy^{51,52} selected for the guideline update are:

- Clinical signs: *Eczema Area and Severity Index (EASI)*;
- Overall disease severity as measured by the composite score *SCORing of Atopic Dermatitis (SCORAD) index*;
- Patient-reported symptoms: *Patient-Oriented Eczema Measure (POEM)*;
- Quality of life: *Dermatology Life Quality Index (DLQI)*, *Children's Dermatology Life Quality Index (CDLQI)*, *Infant's Dermatitis Quality of Life Index (IDQOL)*.

Other outcomes selected additionally here:

- Objective SCORAD (*o-SCORAD*);
- Patient-oriented SCORAD (*PO-SCORAD*);
- Investigator's Global Assessment (*IGA*, percentage of patients with IGA of 0 "clear" or 1 "almost clear") if no other objective score is reported;
- Visual analogue scale itch (*VAS-itch*);
- Typical adverse events: clinically relevant serious adverse effects of each systemic treatment, such as infection with all agents, conjunctivitis with the new biologic agents, renal function impairment and hypertension with cyclosporine, and gastrointestinal side effects with methotrexate.

^b The other outcomes recommended by the HOME initiative were: NRS, RECAP and ADCT but these have only been recently recommended and validation studies are still ongoing and trials will not measure outcomes with these instruments yet.

3. Existing evidence and clinical guidance

This section provides a general overview of existing systematic review and guidelines.

Systematic reviews

The Centre for Evidence Based Dermatology (CEBD)³⁶ in Nottingham, United Kingdom, provides an overview of systematic reviews (monthly updates) since 2000, with the objective to inform clinicians about new guidelines and systematic reviews on atopic eczema. *Therefore, we did not perform a scoping search for systematic reviews. Depending on the final key questions chosen to be answered in the guideline, the CEBD lists will be used as a first resources for evidence.*

Guidelines

We conducted a non-exhaustive search^c in the Guidelines International Network (G-I-N), National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), ECRI Guidelines Trust, Association of the Scientific Medical Societies (AWMF) and PubMed databases for existing guidelines published during the last 5 years, see appendix S1.

We identified 12 guidelines⁵³⁻⁶⁴: Seven of the 12 identified guidelines were from Europe^{53,55-58,64,65} (only one was published since the last update and is a local adaptation of the European guidelines⁵⁸). Only two guidelines as well as the additional treatment updates of the NICE guideline for atopic dermatitis were evidence-based. Those three guidelines considered for adaptation are listed below, for the AGREE II evaluation (domain 3 only), see appendix S2.

- “Clinical practice guidelines for the management of atopic dermatitis 2018.” Japan⁵⁹
- “Guidelines on Management of Atopic Dermatitis in India: An Evidence-Based Review and an Expert Consensus.”⁶⁰
- “Treating atopic eczema in children aged 12 and under and treating eczema in people over 12.”⁶⁶

4. The purpose and objectives of guideline/ consensus statement

Background:

- New topical and systemic treatments for atopic dermatitis have been developed and approved.
- Several guidelines for the treatment of atopic dermatitis exist, but recommendations vary⁶⁷ and evidence-based recommendations for novel treatments are needed.
- Different prescribing practices between dermatologists across Europe and lack of experience in particular with systemic treatments have been reported⁶⁸. There is therefore a need for current

^c This is a general overview of what guidelines currently exist. Please do let us know if you know of any others.

guidance and treatment algorithms on conventional and emerging therapies. Besides, expert consensus advice on managing patients in special circumstances such as during pregnancy or, for example, with allergic comorbidities is essential ⁶⁹.

- There is also a lack of clear guidance on switching patients from one systemic therapy to another and combined systemic therapy.

Objectives:

- To update the existing European AD treatment guideline.
- To generate recommendations and treatment algorithms on novel and established systemic treatments for atopic dermatitis based on the latest evidence.
- Provide guidance in the management of atopic dermatitis patients during pregnancy and AD patients with allergic comorbidities.
- Provide guidance on systemic drug switching and combination treatment.

5. Targeted users of guideline/consensus statement

- Dermatologists and allergists across Europe.

6. Connecting with relevant other organisations

- We are considering the evidence-based expert and non-expert opinion output of the HOME initiative (See above).
- We are considering the evidence-based expert opinion output of the European Task Force on Atopic Dermatitis (ETFAD). Members of the ETFAD are also in the guideline group, and we will make references to the work of the ETFAD where needed.
- Involvement of patients: patient representatives will be part of the guideline development group. A scoping review concerning patient needs will be conducted.
- A compressive, living systemic review and network meta-analysis (NMA) of systemic therapies is being published in late April 2020 ⁷⁰. Members of the NMA team are also in the guideline group.

7. Stakeholder recruitment

- National societies contributing financially to the EDF guidelines fund are contacted via email with a call for experts; those suggestions are priorities in the selection of experts to become members of the guideline development group (GDG).
- The guideline co-coordinators and the members of the EuroGuiDerm Board of Directors are also invited to suggest members.
- EDF members were invited to self-nominate twice via the EuroGuiDerm newsletter.

8. Other key issues

- Atopic dermatitis is associated with a high burden of disease in Europe ⁷¹, and there is a need for effective and long-term treatment for children and adults with atopic dermatitis ⁷².
- Economic evaluations based on interventions in children and adults are scarce. Resource usage and costs vary according to country and health care systems, making extrapolation from one setting to another difficult ⁷³.
- Interventions for improving access to care, patient education and treatment adherence should be explored. Furthermore, patients' preferences should be taken into account ⁷⁴.

9. Proposed key questions

Evidence-based questions:

- (1) What is the efficacy (improvement in short and long-term disease control [signs and symptoms] as well as quality of life) and safety of conventional and novel systemic therapies for the treatment of AD? This question will be answered in three parts:
 - i. Expert consensus for acute disease/flare control;
 - ii. Evidence-based, 12-16 weeks;
 - iii. Evidence-based, >16-52 week.
- (2) Would changing from one systemic treatment to another lead to benefit in disease control?
- (3) Does combination therapy of systemic treatments lead to additional benefit in disease control and quality of life?

The evidence-based sections will be based on a living systematic review lead by Carsten Flohr⁷⁰.

Consensus-based questions:

- (4) What is the efficacy (improvement in short and long-term disease control) and safety of topical anti-inflammatory therapies of AD?
- (5) What is the effectiveness and safety of different phototherapy regimen (e.g. NB-UVB, PUVA, UVA1) for AD patients?
- (6) What is the effectiveness of different therapeutic patient education regimen used for AD and does therapeutic patient education reduce the risk of patients experiencing side effects from topical and/or systemic treatments?
- (7) What are the important provocation factors for AD (such as climate, allergen exposure (e.g. house dust mite, mould), skin irritants, food allergens, stress, water hardness), and how should patients avoid them?

- (8) What is the optimal skin care regimen for AD patients, for instance regarding bathing (frequency, temperature, duration, bath additives (oils/emollients/bleach), emollient use afterwards yes/no), and showering?
- (9) What is the effectiveness and safety of dietary exclusions or supplements for the treatment of AD?
- (10) What is the effectiveness and safety of different antibacterial, antiviral and antifungal treatments for infectious complications and alongside topical and/or systemic therapy?
- (11) What is the effectiveness and safety of complementary and alternative diagnostic and therapeutic procedures for AD patients?
- (12) What is the effectiveness of psychological/psychosomatic/psychotherapeutic interventions for AD patients?
- (13) What are key differences in the diagnosis and management of pediatric compared to adult AD (consider infants, children and adolescents separately).
- (14) What are key differences in the management of AD in pregnant women?



SCOPING DOCUMENT - APPENDIX S1 SEARCH FOR EXISTING GUIDELINES

Search terms

atopic dermatit* OR atopic eczem* OR neurodermitis (in PubMed additionally with “guideline” in title)

Search date

13 January 2020 (PubMed search limited to years 2017 - 2020)

Title	Organisation(s)	Date	Country/Region	Sources	Comments
Атопічний дерматит. Адапована клінічна настанова, заснована на доказах [Atopic dermatitis. Adapted evidence-based guideline] ⁵³	MoH (UA) - The State Expert Center, Ministry of Health, Ukraine	Jul 04, 2016	Ukraine	G-I-N	language: Ukrainian
Evidence-Based Clinical Practice Guidelines for atopic dermatitis in Traditional Korean Medicine ⁵⁴	KIOM (KO) Korea Institute of Oriental Medicine	Jul 11, 2016	Republic of Korea	G-I-N	-
Atooppinen ekseema [Atopic eczema] ⁵⁵	CC (FI) - Current Care Guidelines / the Finnish Medical Society Duodecim	Feb 03, 2009 (update 2016)	Finland	G-I-N	language: Finnish
Neurodermitis. S2e-LL (DDG) [Neurodermatitis] ⁵⁷	AWMF (DE) - Association of Scientific Medical Societies	Mar 31, 2020	Germany	G-I-N	not evidence-based and is under review (not published)
British Association of Dermatologists' guidelines for the management of contact dermatitis 2017. ⁵⁶	British Association of Dermatologists (BAD)	Feb, 2017	United Kingdom	ECRI	guideline on contact dermatitis
Neurodermitis (S2k) ⁶⁵	AWMF (DE) - Association of Scientific Medical Societies	Mar, 2015	Germany	AWMF	language: German
Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). ⁵⁸	SIDeMaST, ADOI, SIDAPA	Nov, 2019	Italy	PubMed	based on old EDF GL



Clinical practice guidelines for the management of atopic dermatitis 2018. ⁵⁹	Katoh et al.	Dec, 2019	Japan	PubMed	boxes w/ recommendations, use of evidence levels (old Oxford)
Guidelines on Management of Atopic Dermatitis in India: An Evidence-Based Review and an Expert Consensus. ⁶⁰	Rajagopalan et al.	May, 2019	India	PubMed	Key Qs in appendix, use of evidence levels (old Oxford)
Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care. ⁶¹	Sidbury et al.	Sep, 2018	United States	PubMed	summary of 2014 AAD Guidelines
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. ⁵¹	EDF	May, 2018	Europe	PubMed	old EDF GL
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. ⁵²	EDF	Jun, 2018	Europe	PubMed	old EDF GL
Guidelines for the management of atopic dermatitis (eczema) for pharmacists. ⁶²	Wong et al.	May, 2017	Canada	PubMed	-
Japanese guidelines for atopic dermatitis 2017. ⁶³	Katayama et al.	Apr, 2017	Japan	PubMed	-
Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. ⁶⁴	Nowicki et al.	Aug, 2015	Poland	PubMed	-



SCOPING DOCUMENT - Appendix S2: AGREE II evaluation (domain 3 only) of guidelines potentially suitable for adaptation

AGREE II-Domain 3: Rigour of development									
Guidelines	7. Systematic methods were used to search for evidence.	8. The criteria for selecting the evidence are clearly described.	9. The strengths and limitations of the body of evidence are clearly described.	10. The methods for formulating the recommendations are clearly described.	11. The health benefits, side effects, and risks have been considered in formulating the recommendations.	12. There is an explicit link between the recommendations and the supporting evidence.	13. The guideline has been externally reviewed by experts prior to its publication.	14. A procedure for updating the guideline is provided.	Quality score (0%-100%)
Clinical practice guidelines for the management of atopic dermatitis 2018 Kato et al. 2018	PubMed, Japana Centra Veevo Medicina, and Cochrane Library were searched for the relevant literature published by the end of December 2015. But complete search strategy not given	Designs of studies used as references for the determination of the evidence level. Old Oxford was used for level of evidence	The evidence level was an eventual judgment concerning the "quality of evidence" based on evidence concerning important outcomes reached as a consensus of the committee	Recommendations were comprehensively evaluated on the basis of the magnitude of benefits expected from the recommended treatments and balance between the benefits and harm or burdens that may be caused by the treatments in consideration of the evidence level, clinical experience, balance between benefits and harms, values, and wishes for treatment. No information given on how consensus was reached.	In consideration of the evidence level, clinical experience, balance between benefits and harms, values, and wishes for treatment	Each recommendation is followed by a description graph and level of evidence	No information given	No information given	
Rating	2	2	2	2	3	3	1	1	17%
Guidelines on Management of Atopic Dermatitis in India: An Evidence-Based Review and an Expert Consensus Rajagopalan et al. 2019	An extensive literature search was done in MEDLINE, Google Scholar, Cochrane, and other resources. Articles published in the past 10 years were reviewed. But complete search strategy not given	Articles published in the past 10 years were reviewed and recommendations were graded based on the quality of evidence as per GRADE. For level of evidence and strength of recommendation old Oxford was used.	Their discussions were based on literature from clinical research articles and also from their experience and acumen	The members gave their independent views on the preselected recommendations in agree and disagree scale with an Indian perspective. No information given on how consensus was reached.	Unclear if harms and benefits were taken into account for every recommendation. Harms are listed in some recommendation boxes and text.	Each recommendation is presented in a box with level of evidence and evidence is described in the text	No information given	No information given	
Rating	2	2	2	2	2	3	1	1	15%
NICE interactive flowchart: Treating Eczema in people aged 12 and under Treating eczema in people over 12 Last updated: 31 July 2018	For NICE guidelines review questions must be developed and literature searches are planned and carried out. For clinical pathways sources for updates for treatment are listed some of them included the search strategy many updated on the clinical pathway are from STA.	Each technology appraisal included as source had PICO and inclusion and exclusion criteria.	All evidence is appraised and biases also identified also cost are taken into account. Because this is a pathway it was difficult to identify the quality of evidence used for each recommendation.	Appraisal Committee bases its recommendations on the evidence presented, including statements from consultees and commentators and the views expressed by clinical specialists, commissioning experts and patient experts at the Committee meeting. The TSA included in the pathway overlooks comments from stakeholders and experts.	The appraisal committee take into account impact of benefits and harms and also cost-effectiveness, but in the pathway only the recommendations are given. In the sources cited the complete information can be found.	All recommendations and its respective source is given, but no studies are cited in the text or EtD frameworks given, this can only be found checking the source.	Either NICE guidelines or TSA have to be checked by external stakeholders. This is given on a summary table with comments from each stakeholder and actions taken by the appraisal committee.	No information given, but an update is plan for the Eczema treatment in people aged 12 and under guidelines. Also TSA provide dates for possible updates.	
Rating	5	7	6	5	6	5	7	6	85%

EUROGUIDERM GUIDELINE ATOPIC
DERMATITIS GUIDELINE

**EUROPEAN
CENTRE FOR
GUIDELINES
DEVELOPMENT**



**European
Dermatology
Forum**

CHARITÉ
dEBM